KANGSTEM BIOTECH CO., LTD.

217730KOSDAQPharmaceuticals

KANGSTEM BIOTECH CO., LTD. (217730, KOSDAQ) reported KRW 4bn revenue in 2025.

Broker research: target prices and ratings

1 report from 1 firm between 2026-09-28 and 2026-09-28. None of these reports stated a target price.

Newest first. Ratings are as each firm stated them, translated into English. "Not stated" means the report carried no value — it is not a zero.

DateTarget priceRatingFirmAnalyst
Not statedNot statedKorea IR ServiceNot stated

Some publishers here are not securities firms — credit-information agencies and the Korea IR Service publish company analysis but do not issue target prices.

Report titles are not shown: the source lists them in Korean only, and we do not publish our own translation of another firm's headline.

This is a record of what brokers published, not investment advice. It is a sample of broker research — the reports our collection picked up, not every report written on this company — and the range and median describe that sample, not a market consensus. These are statistics, not a verdict.

Source: broker reports collected by SeoulMarkets from Naver Finance's research listing and from brokers' own websites, 2026-06-29 to 2026-10-28.

Compare target prices across Korean biotech and pharma stocks →

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
202112—-2210366Consolidated
202216—-208147Consolidated
202313—-238145Consolidated
20248—-85643Separate
20254—-108169Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
2021—-176%64%-33.1%
2022—-123.8%58.6%-42.7%
2023—-182.8%54.8%-52.2%
2024—-103.2%77.1%-18.5%
2025—-293%84.7%-15.2%

Revenue moved -71.2% between 2021 and 2025.

Net profit was negative in the 5 most recent consecutive years on file. Counted from the 5 years in which the company filed a net-profit line — a year with no filing is skipped, not read as a loss.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 208bn
Close priceKRW 2,210
Listed shares94,054,149
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

When it was founded

The incorporation date on the company's registration record, as filed with Korea's Financial Supervisory Service. This is when the company was legally formed — not when it first listed, and not when the business it grew out of began trading.

Incorporated

Who runs it

Registered representative directors — in Korea this is the office a CEO holds. Filed with the Financial Supervisory Service (DART). A Korean company can register more than one, and the title beside each name is the rank they carry inside the company.

NameTitleBoard seatYears in post
Na Jong-cheon (나종천)Representative Director (CEO)Inside director5 years

Roman spellings are ours, converted from the Korean filing. The person may spell their own name differently in English. The Korean name in brackets is what was filed.

Workforce — a side measure, not the main one

Employees (2025)86
Women50 (58.1%)
Average tenure4.4 years
Annual pay, menKRW 64,000,000
Annual pay, womenKRW 53,000,000
Pay ratio, women to men82.8%

Other companies in Pharmaceuticals

181 listed companies file under this classification. Showing 12.

See the whole Pharmaceuticals list →